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ABSTRACT 
Background: With the advent of highly active antiretroviral therapy, the life expectancy 
of people living with HIV (PLWH) has approached that of the general population. 
Nevertheless, aging PLWH are at an increased risk of certain conditions associated with 
aging, including end-stage renal disease (ESRD). Research characterizing the survival 
experience of PLWH diagnosed with ESRD is still evolving. 
 
Methods: Data from the North American AIDS Cohort Collaboration for Research and 
Design (NA-ACCORD) were used to validate incident cases of ESRD among HIV-
infected adults occurring from January 1995 to December 2010. Pooled logistic 
regression was used to identify risk factors for death post-ESRD diagnosis. Kaplan-Meier 
curves were generated to characterize survival. Standardized mortality ratios (SMRs) by 
age, sex, and race were calculated to compare mortality between the NA-ACCORD 
population and the general population using data from the United States Renal Data 
System (http://www.usrds.org/reference.aspx). 
 
Results: A total of 540 HIV-infected individuals on dialysis, aged 18 to 89, contributed 
23,491 person-months, or 1958 person-years, to this analysis. The median age at ESRD 
diagnosis was 44 years in HIV-infected individuals compared to 60 to 65 years in the 
general population. The median survival after diagnosis in the NA-ACCORD population 
was approximately five years. Older age (≥60 years), elevated total cholesterol, history of 
clinical AIDS diagnosis, CD4+ cell count less than 200 cells/µl, detectable viral load 
(≥200 copies/mL), no ART use, and tenofovir exposure prior to diagnosis were 
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associated with an increased hazard of death after ESRD diagnosis. An age-adjusted 
SMR of 1.09 (95% CI:  0.89, 1.29) suggests that the NA-ACCORD population had 
approximately the same number of deaths as would be expected if the probability of 
death in HIV-infected adults with ESRD was the same as in the general population with 
ESRD. 
 
Conclusions: HIV-related risk factors were more strongly associated with the hazard of 
death among HIV-infected adults with ESRD compared to traditional age-related risk 
factors. The median life expectancy post-ESRD diagnosis was similar between HIV-
infected and uninfected adults on dialysis, even though HIV-infected adults were 
diagnosed with ESRD 15 to 20 years younger compared with the general population. 
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BACKGROUND 
 Since the HIV epidemic began in the early 1980s, survival among infected 
individuals has steadily improved. With the discovery of highly active antiretroviral 
therapy (HAART) in the mid-1990s, the average life expectancy for HIV-infected 
individuals has improved significantly, with estimates approaching that of the general 
population (The Antiretroviral, 2008; Nakagawa et al., 2012; Samji et al, 2013). Since the 
early-HAART era, the number of people living with HIV (PLWH) who are 50 years or 
older has approximately doubled, with over 30% of prevalent HIV cases occurring in this 
age group in the United States, based on the most recent available data (Mahy et al., 
2014; UNAIDS, 2014). The CDC estimates that by 2015, 50% of individuals with HIV in 
the U.S. will be over 50 years old (National Institute on Aging). 
 Despite improvements in survival and treatment, however, PLWH are at an 
elevated risk for non-AIDS related comorbid conditions. For instance, the risk of 
myocardial infarction, renal failure, liver diseases, hypertension, and hepatitis C is 
significantly higher in this population than in the general aging population (Hasse et al., 
2011; Guaraldi et al., 2011). There are multiple potential explanations for this elevated 
risk, including the overlapping risk factors for certain comorbidies and HIV, the chronic 
inflammatory effect of the virus itself, and the toxicities associated with antiretroviral 
therapy (Deeks, 2009; Deeks, 2011). 
 
End-Stage Renal Disease in the General Population and HIV+ Adults 
 Renal complications in PLWH are prominent among these comorbid conditions, 
and they have persisted in the era of antiretroviral therapy. End-stage renal disease 
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(ESRD) is the last stage of chronic kidney disease and describes the most severe and 
permanent form of these complications. ESRD is defined as the point in which a patient’s 
kidneys fail to function without the assistance of renal replacement therapy, specifically 
hemo- or peritoneal dialysis or a kidney transplant. In the United States, individuals 
automatically qualify for Medicare at diagnosis of ESRD, regardless of age. Medicare 
and Medicaid cover the cost of dialysis (“Coverage,” 2014). The United States Renal 
Data System (USRDS) collaborates with the Centers for Medicare and Medicaid, among 
other organizations, to establish full capture of ESRD patients in the U.S. (United States 
Renal, 2014). In order to characterize trends in survival among HIV+ ESRD patients, the 
experience among the general U.S. population, as described by USRDS, will serve as the 
reference group.   
  USRDS data suggest that the incidence of ESRD among the general population 
has been plateauing in recent years. In 2012, the number of new cases was approximately 
115,000, and the number of prevalent cases was under 650,000 (United States Renal, 
2014). There is a notable racial discrepancy among the distribution of ESRD cases, 
however, with the black population at an over three-fold increased risk of developing this 
disease compared to the white population (United States Renal, 2014). Overall, the mean 
age of ESRD patients is estimated to be approximately 60 to 65, with the majority of the 
disease burden falling on patients over this age (United States Renal, 2014).  
 ESRD trends among patients with HIV, however, are less well characterized. As 
previously mentioned, renal complications and ESRD remain prominent among PLWH – 
particularly aging PLWH. With the advent of HAART and accompanying improvements 
in HIV management, the incidence of certain ESRD-causing conditions, such as HIV-
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Associated Nephropathy (HIVAN), has decreased significantly (Abraham et al., 2014; 
Ross & Klotman, 2004). Nevertheless, the risk of ESRD remains elevated among PLWH, 
with estimates suggesting the risk could be up to 20 times higher (Jotwani et al., 2012; 
Bickel et al., 2013; Abraham et al., 2014). Some of the traditional risk factors for ESRD 
include high blood pressure, smoking, hepatitis C, and drug use, which are more common 
among HIV+ individuals (Seaberg et al., 2005; Perneger et al., 2001). However, after 
accounting for differences in risk factors for ESRD in HIV+ adults and the general 
population, HIV+ adults still have an increased risk of ESRD compared to similar, 
uninfected adults (Abraham et al., 2014). In addition, there is evidence to suggest that 
antiretroviral treatments, specifically tenofovir, increase the risk of renal complications, 
including ESRD, due to their nephrotoxic effects (Izzedine et al., 2009).  
 Previous studies have examined the risk factors for developing ESRD among 
PLWH. As in the general population, black individuals with HIV are at a significantly 
higher risk of progressing to ESRD (Lucas et al., 2008, Abraham et al., 2014). Comorbid 
conditions such as hypertension, diabetes, and cardiovascular disease have been 
identified as risk factors, as have HIV-associated risk factors such as low CD4+ cell 
count, high HIV viral load, and hepatitis C co-infection (Jotwani et al., 2012).  
 
Mortality After ESRD in the General Population and Among HIV+ Adults 
 In the general population, survival post-ESRD diagnosis depends on myriad 
factors, including age, race, and sex. Overall, however, the most recent USRDS data 
estimate that the 5-year survival is approximately 45% among patients on dialysis, and 
this trend has been steadily increasing from year to year (United States Renal, 2014). 
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Research on survival post-ESRD diagnosis in HIV-infected adults has yielded varying 
estimates of 5-year survival. Many studies do not report 5-year survival, or truncate 
Kaplan-Meier curves before this time period because so few patients survive beyond this 
point (Ahuja et al., 2002; Atta et al., 2007). Studies that do report 5-year survival have 
estimates that range from 9% to 35% (Rodriguez et al., 2003; Soleymanian et al., 2006). 
However, these studies have follow-up that ended nearly 10 years ago; it is possible that 
survival has improved since that time. 
 
Objectives 
 The objectives of the present study were two-fold. First, we aimed to better 
characterize survival among HIV-infected adults with ESRD. The data, which included 
verified ESRD cases among PLWH, are representative of individuals linked to care in 
North America (Althoff et al., 2012). Traditional and HIV-specific risk factors were 
included as potential risk factors for death among this population. Second, we aimed to 
compare mortality in HIV+ adults with ESRD to mortality in the general population with 
ESRD. USRDS data served as the reference group. Research on this topic has been 
consistently evolving in recent years, perhaps reflecting improvements in HIV 
management over time. These objectives were meant to further elucidate and expand this 
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METHODS 
Study Population 
 The North American AIDS Cohort Collaboration on Research and Design (NA-
ACCORD) is a consortium of single- and multi-site HIV cohorts in the United States and 
Canada. It was created in 2006 as one of seven members of the International 
Epidemiological Databases to Evaluate AIDS (IeDEA) network established by the 
National Institute of Allergy and Infectious Diseases. NA-ACCORD contributing cohorts 
provide data on both HIV-infected and HIV-uninfected individuals to facilitate research 
and characterize HIV care across North America. The consortium includes over 25 
cohorts and 200 clinical sites, including academic research centers, hospitals, and private 
practices in the United States and Canada (“North American,” 2015; Kitahata et al., 
2015). Clinical, demographic, and behavioral data are collected at varying intervals – 
depending on cohort protocol – and merged at the NA-ACCORD Data Management Core 
at the University of Washington in Seattle (Gange et al., 2007).  
 
ESRD Validation 
 12 participating NA-ACCORD cohorts provided clinical data, including patient 
medical histories, medications, and laboratory measurements, which were utilized to 
verify cases of end-stage renal disease (ESRD) among HIV+ adults. 
The ESRD screening and verification process has been published previously (Kitahata et 
al., 2015). Briefly, researchers first used a screening algorithm to identify potential HIV+ 
individuals with ESRD in any of these 12 cohorts. Patients with a positive ESRD 
diagnosis code, evidence of a kidney transplantation, evidence of dialysis, or two 
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estimated glomerular filtration rates (eGFR) <30 ml/min/1.73m2 separated by more than 
90 days with no intervening eGFR measurement ≥30 ml/min/1.73m2 were screened as 
“positive” for ESRD (N = 822) (Abraham et al., 2014). Of these screened cases, those 
with medical-record confirmed dialysis, renal transplantation, or arteriovenous fistula 
(AVF) placement and dialysis were considered “verified” (N=620) (Kitahata et al., 2015; 
Abraham et al., 2014).  Of these 620 verified cases, 601 had a known year of ESRD 
diagnosis according to the criteria above; these 601 individuals are considered 
“validated” ESRD cases (Kitahata et al., 2015).   
 For the purposes of this analysis, only subjects on dialysis – either hemodialysis 
or peritoneal dialysis – were included. Survival differs significantly between ESRD 
patients with a kidney transplant compared to those on dialysis, with transplant recipients 
living longer (United States Renal, 2014). Additionally, only individuals who were 
validated and diagnosed prior to the cohort-level “ESRD observation window” close date 
were included in this analysis. Those with a known diagnosis date after observation 
concluded were excluded. Additionally, when accounting for “late entries,” some 
individuals were lost to follow-up or died before their adjusted time of entry. As a result, 
the outcome – death – could not be observed for these individuals if it did occur. They 
were excluded from the analysis. The final analytic sample was comprised of 540 HIV+ 
adults over 18 years of age with a validated date of ESRD diagnosis. 
 
Outcome 
 The outcome measure was death. The NA-ACCORD cohorts participating in the 
ESRD validation procedure contributed information about death through medical records, 
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the National Death Index, or active study follow-up. For the purposes of this analysis, the 
month and year of death was utilized. If there was no date of death, the subject was 
considered to be alive (event-free) and was censored at the end of follow-up. 
 
Risk Factors 
Time-Fixed Risk Factors 
 Race was recorded at entry into each cohort. For the purposes of the risk factor 
analysis, race was collapsed into two groups: black or other/unknown. In this study 
sample, “other” groups included white, Hispanic, Asian/Pacific Islander, and multiracial. 
Because the majority of the study population was black, race was categorized in this way. 
However, to compare mortality rates in the NA-ACCORD population with those in the 
general population, race was divided into black, white, and other/unknown. HIV 
transmission risk was also considered time-fixed for this analysis. Risk groups included: 
heterosexual contact (including high-risk contact), male-male sexual contact, injection 
drug use, and other/unknown. “Other” HIV transmission risk groups included 
hemophiliacs, recipients of blood transfusions, and healthcare or laboratory workers. As 
the risk for contracting HIV is low in each of these populations, they are grouped 
together. If individuals belonged to multiple risk groups (for example, heterosexual 
contact and injection drug use), the behavior that carries a larger risk of HIV transmission 
was utilized. Cigarette smoking status was considered an “ever versus never” event. 
Evidence of a smoking diagnosis, self-reported smoking, or notation of smoking in the 
medical record indicated a history of smoking. Missing smoking status was imputed 
using multiple imputation. 
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 Hepatitis C and hepatitis B were recorded as time-fixed events if they occurred at 
any point during NA-ACCORD observation. Hepatitis C was measured as either a 
positive hepatitis C antibody test, detectable hepatitis C RNA, or the presence of an HCV 
genotype test. Hepatitis B was measured as a positive hepatitis B surface antigen test, 
positive hepatitis B E antigen test, or ever having detectable hepatitis B DNA. 
Commonly, Hepatitis B and C infection precede HIV infection, but individuals are not 
officially diagnosed until they are linked to care. As a result, the date of diagnosis is 
likely later than the actual date of infection. For the purposes of this analysis, therefore, a 
positive Hepatitis C or hepatitis B diagnosis at any point was treated as “positive” for the 
entire study period. Tenofovir exposure prior to ESRD diagnosis was a time-fixed risk 
factor measured at study entry. Prior exposure included individuals who were on 
tenofovir for one month or longer prior to ESRD diagnosis; shorter durations were not 
considered true “exposures.” There have been reports that tenofovir – which is 
considered widely effective against both HIV and hepatitis B – could have nephrotoxic 
side effects (Fernandez-Fernandez et al., 2011). It was included in this analysis to further 
examine the potential relationship between tenofovir, ESRD, and death after ESRD 
diagnosis. 
 
Time-Varying Risk Factors 
 Age was defined as the calendar year minus the subject’s year of birth. Statin use 
was defined as the date statins were prescribed. Patients prescribed any of the following 
medications are considered “statin users”: cerivastatin, fluvastatin, lovastatin, prvastatin, 
rosuvastatin, simvastatin, combination of pravastatin and aspirin, combination of 
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atorvastatin and amlodipine, combination of ezetimibe and simvastatin, pitavastatin, and 
a combination of lovastatin and niacin. Diabetes was defined using the date of diagnosis. 
Diabetes diagnosis date was the earliest date at which one of the following occurred: a 
measurement of HgA1C >6.5%; a record of prescribed oral hypoglycemic or insulin; one 
or more ICD-9 codes for diabetes plus treatment with an oral hypoglycemic or insulin; or 
two random glucose ≥200 mg/dL. Hypertension was defined as the earliest date at which 
one of the following occurred: a record of prescribed anti-hypertensive medication; or the 
average of at least 2 systolic blood pressure measurements ≥140 mmHg or diastolic blood 
pressure measurements ≥90 mmHg over a 1.25 year time window. Patients with a total 
serum cholesterol >240 mg/dL were considered to have elevated total serum cholesterol. 
Baseline statin use, diabetes, hypertension, and elevated total serum cholesterol were 
measured in the window prior to or within nine months after study entry. History of 
clinical AIDS was defined by the date of first diagnosis of an AIDS-defining illness as 
outlined by the International Statistical Classification of Diseases and Related Health 
Problems (ICD-9) codes.  
 CD4+ cell count was categorized as <200, 200-349, 350-499, or ≥500 cells/µL. 
CD4+ cell count was measured at study visits, and it was carried forward for a maximum 
of 1.5 years (18 months) until it was set to “missing.” HIV viral load was dichotomized 
as “detectable versus undetectable” at the level of 200 copies/mL. Like CD4+ cell count, 
viral load measurements were carried forward for a maximum of 1.5 years before being 
set to “missing.” Baseline CD4+ cell count and viral load were measured in the window 
of 1.5 years prior to, to 6 months after study entry. ART use was defined as having been 
on any number of ART drugs in the month.  
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Missing Data 
 Risk factor missing data were handled differently depending on the variable. For 
two conditions, diabetes and elevated total cholesterol, a lack of definition elements 
measured in an individual was considered evidence of no disease, after taking into 
account the time periods (“observation windows”) in which these elements were 
measured in each participating cohort.  Presumably, patients showing clinical signs of 
either of these conditions would have been tested for them. The following variables also 
had missing data: hepatitis C infection, hepatitis B infection, and cigarette smoking. 
However, the missing data did not exceed 20% for any of these variables, so available 
case analysis was utilized. Cigarette smoking was imputed using multiple imputation via 
logistic regression. The data were assumed to be missing at random. The following 
covariates were used to impute the missing values for cigarette smoking: death, follow-up 
time, cohort, age at entry, sex, race, HIV transmission risk, CD4+ count at entry, viral 
load at entry, and ART use. Five imputed datasets were created for this purpose. In this 
analysis, only one of the five dataset was utilized. Imputed values are not considered 
missing. 
 There were no missing data for the outcome. Patients without a death date were 
considered alive at administrative censoring in December of 2010. 
 
Statistical Analyses 
 The purpose of this risk factor analysis was to describe and generate hypotheses. 
As there was no specific exposure of interest, there were no hypothesized confounders.  
Univariate analyses were conducted using chi-squared tests for proportions to determine 
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baseline differences in demographic, behavioral, and clinical characteristics between 
HIV+ individuals with ESRD who died under observation compared to those who did 
not. The Kruskal-Wallis test was used to determine baseline differences between 
medians.  
  Study entry was defined as the month and year of ESRD diagnosis, provided that 
it occurred during each cohort’s ESRD “observation window.” Individuals with a 
diagnosis after the observation window were excluded, as they could no longer be 
followed up for the event of interest. Those with a diagnosis prior to the observation 
window and after cohort initiation date were included as “late entries.” To account for 
immortal person-time in which no events could have occurred, study entry for these 
subjects was the month from ESRD diagnosis.  Study exit for each subject was death or 
censoring on December 31, 2010, two years after the last CD4+ cell or viral load 
measurement (as a measure of loss-to-follow-up), or 10 years post-ESRD diagnosis – 
whichever occurred first. Since it was possible that subjects could have missed a number 
of study visits before returning, they were not considered “lost to follow up” until two 
years after their last CD4+ cell or viral load measurement. Furthermore, since few 
individuals survived longer than 10 years post-ESRD diagnosis, data were sparse past 
this point. As a result, the analysis was restricted to within 10 years post-diagnosis. 
Individuals surviving longer than this point were censored at 120 months. 
 Pooled logistic regression models were utilized to explore the crude association 
between hypothesized risk factors and the outcome, death. Since the data were collected 
at varying intervals, the smallest of which being at the one-month level, the unit of 
analysis was person-months. Given this discrete unit of measurement, pooled logistic 
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regression was the most appropriate method of analysis. Time was parameterized in the 
model at the month level. Although not all crude associates were statistically significant, 
all risk factors were included in the final pooled logistic model, as the purpose of this 
analysis was to generate hypothesis about risk factors. Kaplan-Meier survival curves, 
stratified by important risk factors for interest, were generated to characterize and 
visualize survival trends.  
 Lastly, to compare age-, sex- and race-adjusted mortality rates after ESRD in 
HIV+ adults in the NA-ACCORD with the general population, publicly available 
USRDS mortality rates, stratified by these same risk factors, were utilized. Due to the 
relatively small number of events (deaths) in the NA-ACCORD population, an indirect 
standardization technique was employed to yield a standardized mortality ratio (SMR). 
Information from the years 2005 to 2010 was combined to compare rates between the 
USRDS population and the NA-ACCORD study population, as there was ample 
information and person-time contributed in these years.  
 The number of expected deaths was generated for the NA-ACCORD population 
based on the mortality rates in the general population (per one person-year) multiplied by 
the person-years at risk in the study population (calculated by dividing the person-months 
in the analysis by 12). The number of observed deaths was then divided by the number of 
expected deaths to yield an SMR. An SMR over the value of one suggested that there 
were more deaths observed in the study population than would be expected given the 
rates from the general population; an SMR under the value of one suggested the opposite. 
95% confidence intervals were calculated to determine if there was a statistically 
significant difference between the two populations. The upper limit of the confidence 
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interval was equal to the SMR plus 1.96 multiplied by the square root of the observed 
number of events divided by the expected number of events. The lower limit was equal to 
the SMR minus 1.96 multiplied by the square root of the observed number of events 
divided by the expected number of events. 
   For the purposes of estimating the SMR, age was adjusted according to age 
groups specified by the USRDS. Sex was male and female, and race was collapsed into 
white, black, and other. 
 
Sensitivity Analyses 
 Although data collection at the month level was considered a discrete time metric, 
information collection at this level was still relatively precise. Further, the hazard in each 
person-month was likely reflective of the continuous time hazard rate. Finally, we 
believed the hazard for death was truly continuous. Therefore, complementary log-log 
models as well as Cox proportional hazards models (with Efron’s method for ties) were 
run in order to compare results with those from the pooled logistic regression model.  
 In each of these models, there was an assumption that either the hazard odds or 
the hazard was constant in each time period. With respect to a specific risk factor, its 
effect must have been the same throughout all time periods. In order to check that this 
assumption was not violated with the risk factors included in the model, proportionality 
was examined using Schoenfeld residuals. Additionally, ln(-lnS(t)) (survival time) curves 
were plotted versus the ln of analysis time for any risk factor that required further 
assessment based on the Schoenfeld results. If the two curves remained parallel over 
follow-up time, the proportional hazards assumption was not violated.    
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 Data management was performed using SAS version 9.3. Data analysis was 
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RESULTS 
Analytic Sample 
 601 ESRD cases were considered validated with a known month and year of 
diagnosis. Of these patients, two had a kidney transplant; they were removed from the 
analysis so that the final analytic sample would only include dialysis patients. If the 
transplant patients were included in the analysis, the results could have been biased, as 
individuals with kidney transplants are expected to live longer than those on dialysis. 
Additionally, subjects from one cohort with missing comorbidities data were excluded, 
bringing the sample from 599 to 595 patients. Since several of the risk factors for death in 
this analysis were comorbid conditions, patients lacking all comorbidity information did 
not contribute. 
 Of these 595 remaining patients, 25 were diagnosed with ESRD after their cohort-
level ESRD observation window closed. They were excluded from the analysis. Patients 
diagnosed before the observation window began were included as late-entries, and their 
entry time depended on how long before their cohort-level observation window they were 
diagnosed. After adjusting for late entry, some patients did not enter the study until 10 
years after ESRD diagnosis. Since data were sparse after 10 years post-diagnosis, follow-
up time was stopped at this point. Subjects entering after 120 months, therefore, were 
excluded, bringing the sample from 570 to 567. Lastly, after accounting for late entry, 27 
individuals either died or were lost to follow-up before their adjusted entry. The final 
analytic sample included 540 HIV+ adults diagnosed with ESRD. Figure 1 describes the 
selection into the study population. 
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Baseline Characteristics of HIV+ Adults with ESRD 
Demographic Characteristics (Table 1) 
 A total of 540 HIV+ adults aged 18 to 89 years old contributed 23,491 person-
months, or 1958 person-years, to this analysis. The median time contributed was 30 
months, or 2.5 years (IQR = 14 to 56 months; 1.17 to 4.67 years). A total of 255 
participants (47.2% of the study sample) died under follow-up. Characteristics of 
participants can be viewed in Table 1. The median age at ESRD diagnosis was 44 (IQR = 
38, 51), and this age did not differ by survival (age 45 [IQR = 38 to 51] for survivors 
compared to age 43 [IQR = 36 to 50] for those who died, p = 0.05). There was no 
statistically significant difference by sex at baseline; 31% of those who died were female, 
and 28% who survived were female (p = 0.45). However, there was a significant 
difference between these groups with respect to race: participants who died were more 
likely to be black; 91% of those who died and 80% of those who survived were black (p 
= <0.001). Additionally, there was a significant difference in HIV transmission risk group 
between those who died and those who survived, with patients who survived more likely 
to report belonging to the risk group “men who have sex with men” (18% who died 
compared to 29% who survived, p = 0.03). 
 
Clinical and HIV-Specific Characteristics (Table 1) 
 HIV+ ESRD patients who died were more likely to have a history of cigarette 
smoking, with 77% of those who died indicating ever having smoked, compared to 63% 
of those who remained alive (p = 0.001). People who died were also more likely to have 
had a history of AIDS; 49% who died had been diagnosed with AIDS compared to 33% 
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who survived (p = <0.001). Individuals with a history of statin use were more likely to 
remain alive than those reporting no statin use (9% of those who died and 20% of those 
who survived, p = <0.001). Those who remained alive were also more likely to have a 
history of hypertension, at 62% compared to 40% among those who died (p = <0.001). 
ESRD patients who died under follow-up were statistically significantly more likely to 
have a low CD4+ cell count, a detectable viral load, and not be on an ART regimen 
(Table 1). 
 
Survival After ESRD Diagnosis 
 Figure 3, Figure 4, Figure 5, and Figure 6 are Kaplan-Meier survival curves 
estimating the survival experience of the HIV+ population with ESRD in NA-ACCORD. 
Figure 3 represents the overall survival estimate. Based on this curve, the median survival 
post-ESRD diagnosis was approximately five years, or 60 months. Figure 4 is the 
survival estimate, stratified by race. As the graph demonstrates, the median survival for 
black subjects was close to the overall median survival, at approximately 60 months. The 
median survival for “other” race, however, was significantly better, although the exact 
estimate could not be determined due to sparse data. The log-rank test for equality of 
survivor functions had a p-value of 0.005, confirming that the survival experience 
between the races was significantly different. 
 Figure 5 is the Kaplan-Meier curve for survival, stratified by sex. The curves were 
consistently close to each other throughout follow-up time, with the median survival for 
both males and females approximately 60 months. The log-rank p-value suggested that 
there was no difference by sex in terms of survival (p = 0.33). Figure 6 displays the 
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survival curves by baseline age of study participants. Survival appeared best for those 
between the ages of 50 and 59 in the first 60 months, but past 60 months, the curves for 
all age groups appeared similar. The log-rank test suggested there was no difference in 
survival among these baseline age groups (p = 0.63). 
 
Hazard by Month 
 Figure 2 represents a visualization of the observed hazard by month from ESRD 
diagnosis in this population. At each month from diagnosis, the number of deaths was 
divided by the number of patients at risk and plotted. Until month 120, in which the data 
were sparse and surviving subjects were censored, the hazard appeared relatively stable 
over time. The hazard was slightly elevated in the first one or two years -- until 
approximately 30 months. The hazard decreased at approximately year five, month 60. 
Overall, the hazard was small in each month. 
 
Risk Factors for Death: Results from Univariate Analyses 
 The univariate relationships between hypothesized risk factors for death and the 
outcome are presented in Table 2. Age and sex were not statistically significantly 
associated with death in the univariate models. “Other” race, including white, Hispanic, 
Asian/Pacific Islander, and multiracial, was associated with a reduced hazard of death 
(HOR: 0.55, 95% CI: (0.36, 0.84). Men who have sex with men was the only HIV 
transmission risk group to have a statistically significant relationship with death. The 
hazard odds ratio of death in this group was 0.66 (95% CI: 0.47, 0.94), suggesting that 
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men who have sex with men had lower hazard odds of dying than the reference group in 
this population – those with an HIV transmission risk of heterosexual contact. 
 Hepatitis C, hepatitis B, diabetes, and elevated total cholesterol did not have a 
statistically significant association with death in the univariate models. The hazard odds 
of death among cigarette smokers, however, were nearly 50% higher compared to those 
who do not smoke (HOR: 1.48, 95% CI: 1.02, 2.15). Hypertension and history of statin 
use were both protective of death, with hazard odds ratios of 0.67 and 0.61, respectively 
(95% CIs: 0.52, 0.86; 0.41, 0.91). The hazard odds of death among subjects with a history 
of clinical AIDS were 2.63 times higher than those without AIDS (95% CI: 2.03, 3.41).   
 As CD4+ cell count increased, the hazard of death decreased. There was a 
statistically significant reduction in hazard odds with each increasing CD4+ cell count 
group in the univariate analyses. The hazard odds of death in the highest CD4+ cell group 
(≥500 cells//µl) was approximately 70% times lower than in the lowest group (<200 cells/ 
µl) (HOR: 0.34, 95% CI: (0.21, 0.55). Subjects with a detectable viral load had over three 
times the hazard odds of death compared to those who were virally suppressed at the 
level of 200 copies/mL (HOR: 3.38, 95% CI: 2.38, 4.80). Patients on ART therapy had a 
75% reduction in hazard odds of death compared to those not on ART (HOR: 0.15, 95% 
CI: 0.11, 0.21). Prior tenofovir exposure was not significantly associated with death in 
the univariate analyses. 
 
Risk Factors for Death: Results from Multivariate Analysis 
 Results from the multivariate pooled logistic analysis are displayed in Table 2. 
Nearly all hypothesized risk factors for death among HIV+ ESRD patients were included 
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in the final model. As anticipated, not all risk factors were statistically significantly 
associated with death in the unadjusted models. However, the goal of this analysis was to 
generate hypotheses about potential risk factors; therefore, including the full model 
seemed appropriate, despite the level of significance in the univariate associations. HIV 
transmission risk group was the only original risk factor not included in the final model, 
as injection drug use, one of the risk behaviors, was considered to be collinear with 
hepatitis C infection. 
 Death had a “U-shaped” relationship with age in this analysis. Patients under the 
age of 40 seemingly had higher hazard odds of death than those aged 40-49, which was 
the reference group. Ultimately, however, this association was not statistically significant. 
Patients 60 years or older had a two times higher hazard of death at all time points 
compared to patients aged 40-49, and this increased hazard was significant (HOR: 2.29, 
95% CI: 1.29, 4.07). Sex and race were not predictive of death in this population. Of the 
comorbid conditions assessed, only elevated total cholesterol (>240 mg/dL) and 
hypertension were significantly associated with death. Patients with elevated total 
cholesterol had approximately 50% increased hazard odds of death compared to those 
with normal cholesterol levels (HOR: 1.57, 95% CI: 1.13, 2.19). Those with hypertension 
had nearly 30% decreased hazard odds of death compared to those without hypertension 
(HOR: 0.70, 95% CI: 0.49, 0.99). A history of clinical AIDS diagnosis increased the 
hazard odds of death by over two-fold, with a hazard odds ratio of 2.41 (95% CI: 1.69, 
3.45). Patients in the highest CD4+ cell group had 50% reduced hazard odds of death 
compared to those in the lowest CD4+ cell group, but the groups in between were not 
statistically significantly associated with lower hazard (HOR: 0.46, 95% CI: 0.25, 0.85). 
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Patients not on ART therapy had over 75% higher hazard odds of death compared to 
those not on ART therapy (HOR: 0.12, 95% CI: 0.08, 0.19). The hazard odds ratio for 
individuals exposed to tenofovir before ESRD diagnosis compared to those without this 
exposure was 1.71 (95% CI: 1.09, 2.70). 
 In general, some factors that were significantly associated with death in the 
univariate analyses were not associated in the final pooled logistic model, and vice versa. 
Being in the oldest age group (60 years or older), having elevated total cholesterol, and 
prior tenofovir exposure were associated with death in the multivariate model, but not in 
the univariate model. Non-black race, cigarette smoking, hypertension, and certain CD4+ 
groups were associated only in the univariate analyses.  
 
Risk Factors for Death: Results from the Sensitivity Analyses 
 A complementary log-log model and Cox proportional hazards model were both 
run to compare results from the pooled logistic model. The results from the 
complementary log-log model are displayed in Table 3. As expected due to the small (< 
0.50) hazard in each person-month, the unadjusted and adjusted estimates in Table 3 were 
almost identical to those from the univariate and multivariate pooled logistic model in 
Table 2. The largest change in estimate was less than one whole digit. The results from 
the Cox proportional hazards model are displayed in Table 4.  Again, the results from this 
model were virtually the same as the other two models.  
 To assess whether the proportional hazards assumption was violated, in the Cox 
model, ln(-lnS(t)) (survival time) curves were plotted for each risk factor versus the ln of 
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analysis time. In all cases, the difference between the curves was relatively parallel, 
suggesting that the assumption was not violated.   
  
Standardized Mortality Ratios 
 In order to compare mortality rates after ESRD diagnosis in the NA-ACCORD 
population to those in the general U.S. population, age-, sex-, and race-adjusted 
standardized mortality ratios (SMR) were calculated for the years 2005 through 2010, 
combined. 
 The SMR, after adjusting for age, was 1.09, which suggests that the number of 
observed deaths was approximately the same as would be expected if HIV+ adults with 
ESRD had the same probability of dying as the general population with ESRD, after 
accounting for age (95% CI: 0.89, 1.29) (Table 5). The sex-adjusted SMR was 0.59, with 
a 95% confidence interval of 0.48 to 0.70. The interpretation of this SMR is that the 
number of observed deaths was fewer than would be expected if the HIV+ adults with 
ESRD had the same probability of dying as the general population with ESRD (Table 6). 
Here, however, there was no adjustment for age. Lastly, the race-specific SMR was 0.66, 
with a 95% CI of 0.52 to 0.79 (Table 7). Again, the interpretation suggests that the 
number of observed deaths in the NA-ACCORD population was lower than expected 
based on USRDS data. This SMR, like the sex-adjusted, also did not account for age. We 
were unable to adjust for age, sex, and race simultaneously because the mortality rates for 
each stratum of these three risk factors were not available from USRDS. 
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DISCUSSION 
 This analysis sought to address several questions with respect to renal 
complications in PLWH. First, utilizing data from verified cases of ESRD in the NA-
ACCORD cohort, this analysis identified risk factors for death among HIV+ adults 
diagnosed with ESRD. These same data were used to characterize survival after 
diagnosis, stratified by important demographic factors. Second, this study compared age-, 
sex-, and race-adjusted mortality rates after ESRD diagnosis in the NA-ACCORD with 
those in the general population based on USRDS estimates. The resulting calculations, 
the standardized mortality ratios, described the mortality experience of HIV+ patients 
with ESRD compared to that of the general population with ESRD. 
 
Risk Factors for Death 
 Overall, the results from the primary analysis – the pooled logistic model – were 
nearly identical to those from the complementary log-log and Cox proportional hazards 
models examined as sensitivity analyses. The results from the pooled logistic regression 
were interpreted as hazard odds ratios, and the results from the other models were 
interpreted as hazard ratios. Because the discrete time period was so small in the pooled 
logistic model, however, the hazard was also small in each time period (Figure 2). For 
this reason, the hazard odds ratios approximated the hazard ratios. Throughout the 
discussion, therefore, the term “hazard” rather than “hazard odds” will be utilized.  
 Adjusted results from the regression models identified the risk factors associated 
with death in the HIV+ sample with ESRD. Demographically, only subjects in the oldest 
age group, over 60 years old, had a significant increased hazard of death compared to the 
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reference group of 40-49 years. This result was not surprising given that this group had 
no upper bound, and increasing age increases the risk of death in general. The 40 years 
and below category came close to statistical significance, which was also not surprising, 
since there were relatively few subjects with ESRD at this comparatively early age. 
Perhaps HIV+ patients under the age of 40 who develop ESRD have worse overall health 
than their peers, which could dictate why they experience this condition early. This poor 
health might also account for their increased hazard of death after ESRD diagnosis. 
 There was no significant racial difference with respect to progression to death in 
the multivariate analysis. Previous studies, both in HIV-infected and uninfected 
individuals, suggest that the black population experiences a higher burden of ESRD. 
Whether this population is also at an increased risk for death post-diagnosis is unclear, 
particularly since this NA-ACCORD study sample is 85% black. In this case, the lack of 
significance could have been due to the composition of the study population; there were 
relatively few subjects of other races, and even fewer outcomes observed in these 
populations. Future analyses with different study populations may elucidate the 
relationship between race and risk of death after diagnosis.  
 Of the traditional risk factors for developing ESRD, only elevated total 
cholesterol and hypertension were significant risk factors for death in this population. 
There is evidence to suggest that hepatitis C, hepatitis B, and smoking increase the risk of 
developing ESRD; however, none is associated with increased hazard of death in this 
analysis (Lee et al., 2014; Chen et al., 2014). Although literature examining risk factors 
for death after ESRD diagnosis in both the HIV+ and uninfected population is relatively 
sparse, diabetes has been found to be associated with both the risk of developing and the 
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risk of dying from ESRD (Lowrie & Lew, 1990). Nevertheless, diabetes exhibits no 
relationship with death in the NA-ACCORD population. Overall, however, relatively few 
individuals were diagnosed with hepatitis B and diabetes in this population, which could 
explain the lack of association. 
 Hypertension’s protective effect against death was only marginally significant, 
with an upper 95% CI limit of 0.99. Hypertension is one of the most prominent risk 
factors for ESRD; however, there is no previous evidence or biological rationale to 
suggest that it would reduce the hazard of death after ESRD diagnosis. In the NA-
ACCORD sample, patients were considered hypertensive if they had a record of 
prescribed anti-hypertensive medication. Based on this criterion, it seems possible that 
the small protective effect demonstrated in the model could be related to linkage to care. 
Patients who were classified as hypertensive in this sample may be largely the same 
patients who were in care and managing their comorbid conditions. Perhaps individuals 
in this sample who were not classified as hypertensive are those who had unmanaged 
hypertension. If this was the case, then hypertension might look protective because those 
diagnosed are those linked to care. 
 In general, HIV-specific risk factors were more strongly associated with the risk 
of death in this population compared to the comorbidities described above. A clinical 
history of AIDS doubled the hazard of death after ESRD diagnosis, after adjusting for 
other HIV-specific factors such as CD4+ cell count, HIV viral load, and ART therapy. 
There are several potential explanations for this increased risk. Firstly, it is possible that 
the subjects diagnosed with AIDS were those who had been infected with HIV longer. 
These adults were more likely to have increased damage to their immune system, which 
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could have translated into worse outcomes after being diagnosed with a comorbid 
condition such as ESRD. Furthermore, patients diagnosed with AIDS in a time in which 
potent antiretroviral therapy was available might be patients who were not connected to 
care for several reasons. In general, those not connected to care are more likely to have a 
myriad of negative health conditions – some of which may not have been captured or 
adjusted for in this analysis. 
 Those with a CD4+ cell count above 500 cells/µl had a reduced hazard of death 
after ESRD diagnosis compared to those with a count below 200 cells/µl. Patients with 
CD4+ counts above 200 and below 500 cells/µl, however, did not have a statistically 
significant difference in risk compared to the lowest group in this analysis. Overall, 
patients with a high CD4+ count were likely to be patients with well-managed HIV and 
well-managed health in general. Their immune systems were likely stronger, and their 
overall health was likely better, which could have accounted for their reduced risk of 
death from ESRD. Individuals with an undetectable viral load at the level of less than 200 
copies/mL were similarly at a reduced risk of death; the reason was presumably similar to 
that for CD4+ cell count. The cutoff of 200 copies/mL is relatively stringent, provided 
that various cutoffs are used in the literature, with up to 500 copies/mL deemed 
“undetectable.” Particularly with this stringent cutoff, those with an undetectable viral 
load in this sample were likely adherent to their drug regimen and had well-managed 
HIV.  
 Individuals not on ART therapy had over a 75% higher hazard of death than those 
not on ART therapy. This association likely reflects the fact that patients not on ART are 
not managing their HIV and overall health as well as those on a regimen. As with CD4+ 
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cell count and viral load, patients not on ART might not be connected to care, may be 
homeless, may abuse drugs or alcohol, may have mental illnesses, or may have adherence 
issues, amongst other potential economic or social barriers that contribute to poorer 
health outcomes in general. These factors were not directly included in this analysis; it is 
possible that ART therapy captured some of these possibilities and helped explain the 
high hazard of death among this group.  
 Lastly, tenofovir exposure for at least one month prior to ESRD was associated 
with an increased hazard of death among patients with HIV and ESRD in this analysis. 
This risk factor was included in the model because of its potential nephrotoxic side 
effects. There is limited and conflicting literature examining the effect of tenofovir on 
patients with failing kidneys, with some suggesting that increased tenofovir exposure 
results in increased risk of developing chronic kidney disease (Mocroft et al., 2010). In 
this analysis, tenofovir was also associated with increased risk once one is already 
diagnosed with ESRD. Because there is limited literature examining this association to 
date, however, further research is necessary to clarify this association. Nevertheless, after 
adjusting for demographic, traditional, and HIV-specific risk factors, tenofovir increased 
the hazard of death in this population by nearly 70%, which could underscore its 
nephrotoxic effects, even post ESRD diagnosis. 
 
Survival After ESRD Diagnosis 
  The Kaplan-Meier curves stratified by sex, race, and baseline age are shown in 
Figures 3 to 6. Overall, the median survival for HIV+ adults on dialysis post-ESRD 
diagnosis was five years. According to the most recent USRDS data, among patients 
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starting dialysis in 2007, approximately 45% are expected to survive for 5 years (United 
States Renal, 2014). Given these numbers, it appears that the HIV+ sample has similar or 
potentially marginally better survival estimates post-diagnosis. However, it is important 
to note that the average age at diagnosis in the NA-ACCORD sample was 44, whereas 
the average age in the general population, according to USRDS data, is closer to 60 or 65. 
Given these different age distributions, it is critical to age-adjust and then examine 
mortality, a calculation that will be discussed later. 
 As the Kaplan-Meier curves and previously discussed log-rank tests suggest, there 
was seemingly a statistically significant difference in survival between the black and non-
black populations in this sample, with the former having worse survival estimates. Again, 
there is an abundance of evidence to suggest that blacks are more at risk for developing 
ESRD; their survival post-diagnosis is not as clear. One limitation of this sample is that 
there were relatively few patients of “other” race contributing information past five years 
post-ESRD diagnosis. For this reason, the comparison between survival stratified by race 
should be analyzed with caution. Similarly, there appeared to be no significant difference 
in the survival of men and women post-ESRD; however, this sample consisted of twice 
as many males as females. It is possible that the uneven distribution of sex could have 
obscured the relationship between the sexes with respect to survival.  
 
Standardized Mortality Ratios 
 In order to adjust for the different age distributions of the USRDS population and 
the NA-ACCORD population, an age-adjusted standardized mortality ratio was 
calculated based on data from years 2005 to 2010. The results of this calculation suggest 
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that the number of observed deaths in the NA-ACCORD population was approximately 
what would be expected if HIV+ adults with ESRD had the same probability of dying as 
the general population with ESRD. 
 It is important to emphasize that the sex- and race-adjusted SMRs were also 
calculated, and they were both below one. However, they are not adjusted for age. The 
difference in mean age at ESRD diagnosis in the NA-ACCORD population compared to 
the general population is between 15 and 20 years. Given this significant difference, the 
most important adjustment is arguably age. Since there are no publicly available USRDS 
mortality rates adjusting for sex, age, and race combined, the comparison between the 
general population and NA-ACCORD population based on these three factors cannot be 
made at the current time. Given these limitations and the distinct age distributions of the 
two populations, the age-adjusted SMR seems the most appropriate from which to draw 
conclusions, and it appears that the observed deaths in the NA-ACCORD population is in 
keeping with what would be expected based on data from the general population. 
 In summary, the results of this analysis identified some risk factors for death 
among HIV+ adults with ESRD, characterized survival post-diagnosis, and compared 
survival to that of the general U.S. population. Overall, HIV-specific risk factors were 
more strongly associated with the risk of death than traditional risk factors for ESRD in 
this population. The median survival post-diagnosis was approximately five years, though 
the average age of diagnosis was younger than that of the general population, at 44 years 
compared to 60 to 65 years. Lastly, after adjusting for age, the number of deaths observed 
in the NA-ACCORD population was approximately what would be expected based on the 
age-specific mortality rates in the general population. 
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Strengths and Limitations 
 This analysis has some limitations that could potentially be addressed in future 
studies. Perhaps the most significant limitation is the sample size of 540, with the 
majority of cases being male and of black race. This sample size is reflective of the 
intensive screening and verification process for ESRD cases; only those with a known 
month and date of ESRD diagnosis were included. The demographic composition – 
particularly with respect to race – likely reflects the elevated risk of ERSD among 
particular groups. Nevertheless, the limited female subjects and those from other races 
render comparisons among these groups more difficult. Further studies with more 
subjects, events, and demographic diversity might be able to supplement the findings 
presented here. Furthermore, although exposure ascertainment is relatively complete, 
there were some traditional risk factors for which there was limited data. As was 
mentioned previously, relatively few patients were diagnosed with diabetes and hepatitis 
B in this sample. Again, a larger sample might capture more patients with these 
conditions and clarify the association between them and the risk of death from ESRD.  
 Although this analysis demonstrated that HIV-related risk factors were more 
strongly associated with the risk of death compared to traditional age-related 
comorbidities, there was one HIV-specific variable that was not able to be assessed: time 
since seroconversion. Quantifying the time from HIV infection could be important to 
better understand the risk of death among HIV+ ESRD patients. Those infected with HIV 
for longer periods of time presumably have a different health profile than those recently 
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infected. Still, in this sample, the date of AIDS diagnosis was available, which provides 
some insight into how long a particular patient might have been infected.  
 This analysis has several important strengths. Notably, it contributes to the 
growing field of research on aging and HIV. With a steadily increasing proportion of 
HIV+ adults over the age of 50, research on age-related conditions in this population is 
becoming imperative. This analysis seeks to further explore the relationship between one 
important condition of aging – ESRD – and HIV. Previous research has determined that 
the risk of certain conditions of aging is higher among HIV+ individuals; this analysis 
seeks to characterize the trajectory of one such condition.  
 The data used from this analysis are representative of HIV+ patients connected to 
care in North America. All cases of ESRD have been thoroughly screened and verified, 
with a specific date of diagnosis to the month level. Overall, the cohorts that contribute 
data to NA-ACCORD and to this analysis have comprehensive data collection 
procedures, so there is an abundance of demographic, behavioral, and clinical 
information available for analysis. For the purposes of this study, data were updated at 
the month level; the time-varying nature of many risk factors is therefore captured in 
detail.  Moreover, the USRDS data provide a valuable reference group from which to 
draw comparisons in this analysis. It is critical to conduct analyses on only the HIV+ 
NA-ACCORD population in some instances. In order to identify risk factors for death 
among this population, for example, no reference group is needed. However, to evaluate 
the overall affect that HIV might have on the aging process, this reference group is 
crucial.    
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Implications and Future Research 
 This analysis supplements existing literature examining the relationship between 
conditions associated with aging and HIV. Many previous studies have found that 
survival among HIV+ adults with ERSD has been improving with time and 
accompanying advancements in HIV management, though the magnitude of this 
improvement may vary by population (Ahuja et al, 2002; Rodriguez et al., 2003; Atta et 
al., 2007). The median survival estimate post-ERSD diagnosis in this NA-ACCORD 
population is approximately 5 years, which is higher than the results of the previous 
studies and comparable to that of the general ESRD population on dialysis. Since 
improvements are expected with time, the results of this study are in keeping with what 
one might expect based on previous literature. Future research should continue to 
examine this trend and identify factors associated with survival.  
 Importantly, the median age at diagnosis in this study population is between 15 to 
20 years younger than in the general population. There has been conflicting literature 
about the timing of age-related conditions in HIV+ adults, including ESRD, with some 
literature suggesting that ESRD occurs as earlier ages among HIV+ adults, and some 
suggesting that it occurs at the same time as in the general population (Althoff et al., 
2015; Abraham et al, 2014; Rodriguez et al., 2003). Future studies might continue to 
contribute to this discussion, as the implications for screening and treatment could differ 
based on age at diagnosis.   
 Clinically, the results of this study have identified HIV-specific risk factors as 
being more strongly associated with the risk of death from ESRD than traditional age-
associated conditions. This finding emphasizes the continued management of HIV in 
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aging adults, especially with respect to treatment. Certainly, more research should be 
done to clarify the association between other comorbid conditions and the risk of death 
from ERSD, as the limitations of this analysis could have obscured an association if it 
exists. However, these results did identify elevated total cholesterol as an important target 
for intervention, as patients with this condition are at an increased risk of death post-
diagnosis. Overall, these risk factors should be addressed as priorities among HIV+ 
adults diagnosed with ESRD.  
 The timing of ESRD diagnosis and overall survival post-diagnosis in this 
population also has important clinical considerations. The earlier age at diagnosis might 
prompt earlier screening in the HIV+ aging population. Nevertheless, it is encouraging 
that the expected survival in the NA-ACCORD population on dialysis is similar to that of 
the general population, once diagnosed with ERSD. Survival among HIV+ patients looks 
significantly better if these patients are on a form of ART treatment, have high CD4+ cell 
counts, and have undetectable HIV viral loads. Well-managed HIV seems particularly 
critical for managing ESRD in this population. In general, characterizing the experience 
of HIV+ adults with comorbid conditions such as ESRD is imperative to better 
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TABLES AND FIGURES 
Figure 1. Flowchart of Selection into the Study Population 
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Table 1. Characteristics of HIV+ Adults at ESRD diagnosis in NA- ACCORD 
 
Characteristics Dead N= 255 
Alive 
N = 285 P-value 
 
n % n %  
Age (median, IQR)  43 (36-50) 45 (38-51) 0.12 
Age group     0.21 
     <40 years 94 37% 83 29%  
     40-49 years 95 37% 110 39%  
     50-59 years 51 20% 73 26%  
     ≥60+ years 15 6% 19 7%  
Female 80 31% 81 28% 0.45 
Race/Ethnicity     <0.001 
     Black 231 91% 227 80%  
     Non-Black 24 9% 58 20%  
HIV transmission risk     0.03 
     MSM 47 18% 82 29%  
     Heterosexual 114 45% 110 39%  
     IDU 69 27% 61 21%  
     Other/Unknown 25 10% 32 11%  
Hepatitis C infection 92 36% 95 33% 0.03 
     Missing  44 17% 30 11%  
Hepatitis B infection 23 9% 28 10% 0.76 
     Missing  25 10% 23 8%  
Observed Cigarette Smoking 137 54% 145 51% 0.001 
     Imputed values 59 23% 34 12%  
     Missing  26 10% 54 19%  
Diabetes 37 15% 61 21% 0.04 
Hypertension  103 40% 178 62% <0.001 
Elevated total cholesterol (> 
240 mg/dL) 91 36% 95 33% 0.57 
Statin prescription 22 9% 56 20% <0.001 
History of clinical AIDS  126 49% 93 33% <0.001 
CD4+ count (cells/µl)     <0.001 
     <200 127 50% 95 33%  
     200-349 53 21% 53 19%  
     350-499 36 14% 52 18%  
     ≥500 15 6% 40 14%  
     Missing 24 9% 45 16%  
Detectable HIV RNA (≥200 
copies/mL) 185 73% 152 53% <0.001 
     Missing 39 15% 50 18%  
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ART Use 107 42% 154 54% 0.005 
Prior tenofovir prescription 38 15% 46 16% 0.69 
Bold signifies statistical significance (p-value <0.05) 
P-values were estimated using chi square test statistics for a difference in proportions and the Kruskal 
Wallis test statistic for a difference in medians 





Figure 2. Observed Hazard by Month from ESRD Diagnosis in NA-ACCORD  
 
Hazard was calculated by dividing the number of events in each month by the number at risk in each month 
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Table 2. Pooled logistic regression: Crude and adjusted hazard odds ratios for the 





HOR 95% CI aHOR 95% CI 
Age          <40 years 1.14 0.84, 1.55 1.44 0.97, 2.13 
     40-49 years (ref) 1.00 -- 1.00 -- 
     50-59 years 0.87 0.63, 1.21 1.15 0.75, 1.76 
     ≥60 years 1.18 0.76, 1.83 2.29 1.29, 4.07 
Sex          Male 1.00 -- 1.00 -- 
     Female 1.14 0.87, 1.49 1.25 0.90, 1.75 
Race/Ethnicity          Black (ref) 1.00 -- 1.00 -- 
     Non-Black 0.55 0.36, 0.84 0.97 0.57, 1.68 
HIV transmission risk          Men who have sex with men 0.66 0.47, 0.94 -- -- 
     Heterosexual (ref) 1.00 -- -- -- 
     Injection drug users 1.12 0.82, 1.51 -- -- 
     Other/Unknown 0.89 0.57, 1.38 -- -- 
Hepatitis C infection 1.24 0.94, 1.64 0.97 0.68, 1.39 
Hepatitis B infection 0.99 0.64, 1.53 0.98 0.57, 1.68 
Cigarette smoking 1.48 1.02, 2.15 1.24 0.81, 1.91 
Diabetes 0.90 0.64, 1.25 0.92 0.59, 1.44 
Hypertension 0.67 0.52, 0.86 0.70 0.49, 0.99 
Elevated total cholesterol  1.21 0.93, 1.56 1.57 1.13, 2.19 
Statin prescription 0.61 0.41, 0.91 0.69 0.39, 1.20 
History of clinical AIDS  2.63 2.03, 3.41 2.41 1.69, 3.45 
CD4 count (cells/µl)     
     <200 (ref) 1.00 -- 1.00 -- 
     200-349 0.63 0.45, 0.88 0.83 0.55, 1.25 
     350-499 0.55 0.40, 0.82 0.80 0.50, 1.30 
     ≥500 0.34 0.21, 0.55 0.46 0.25, 0.85 
Detectable HIV RNA  3.38 2.38, 4.80 1.82 1.18, 2.80 
ART Use 0.15 0.11, 0.21 0.12 0.08, 0.19 
Prior tenofovir prescription 1.27 0.89, 1.81 1.71 1.09, 2.70 
Bold signifies statistical significance (p-value <0.05) 
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Table 3. Complementary log-log regression: Crude and adjusted hazard ratios for 





HR 95% CI aHR 95% CI 
Age          <40 years 1.13 0.84, 1.54 1.42 0.98, 2.09 
     40-49 years (ref) 1.00 -- 1.00 -- 
     50-59 years 0.87 0.63, 1.21 1.14 0.75, 1.73 
     ≥60 years 1.18 0.76, 1.82 2.25 1.29, 3.93 
Sex          Male 1.00 -- 1.00 -- 
     Female 1.14 0.87, 1.48 1.25 0.91, 1.74 
Race/Ethnicity          Black (ref) 1.00 -- 1.00 -- 
     Non-Black 0.55 0.36, 0.84 0.99 0.58, 1.68 
HIV transmission risk          Men who have sex with men 0.66 0.47, 0.94 -- -- 
     Heterosexual (ref) 1.00 -- -- -- 
     Injection drug users 1.11 0.83, 1.50 -- -- 
     Other/Unknown 0.89 0.58, 1.38 -- -- 
Hepatitis C infection 1.24 0.94, 1.63 0.98 0.69, 1.39 
Hepatitis B infection 0.99 0.64, 1.53 0.96 0.57, 1.63 
Cigarette smoking 1.48 1.02, 2.13 1.23 0.81, 1.86 
Diabetes 0.90 0.65, 1.25 0.93 0.60, 1.44 
Hypertension 0.67 0.52, 0.87 0.70 0.50, 0.98 
Elevated total cholesterol  1.20 0.94, 1.55 1.55 1.13, 2.14 
Statin prescription 0.61 0.41, 0.91 0.69 0.40, 1.20 
History of clinical AIDS  2.59 2.01, 3.35 2.37 1.67, 3.36 
CD4 count (cells/µl)          <200 (ref) 1.00 -- 1.00 -- 
     200-349 0.64 0.46, 0.88 0.83 0.56, 1.25 
     350-499 0.56 0.37, 0.82 0.81 0.51, 1.29 
     ≥500 0.34 0.21, 0.55 0.47 0.26, 0.85 
Detectable HIV RNA  3.34 2.36, 4.72 1.81 1.18, 2.76 
ART Use 0.15 0.10, 0.22 0.13 0.08, 0.20 
Prior tenofovir prescription 1.27 0.89, 1.80 1.70 1.09, 2.66 
Bold signifies statistical significance (p-value <0.05) 
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Table 4. Cox proportional hazards regression: Crude and adjusted hazard ratios of 





HR 95% CI aHR 95% CI 
Age          <40 years 1.13 0.84, 1.54 1.42 0.97, 2.08 
     40-49 years (ref) 1.00 -- 1.00 -- 
     50-59 years 0.87 0.63, 1.21 1.14 0.75, 1.73 
     ≥60 years 1.18 0.76, 1.82 2.22 1.27, 3.88 
Sex          Male 1.00 -- 1.00 -- 
     Female 1.14 0.87, 1.48 1.25 0.90, 1.73 
Race/Ethnicity          Black (ref) 1.00 -- 1.00 -- 
     Non-Black 0.55 0.36, 0.84 0.98 0.58, 1.68 
HIV transmission risk          Men who have sex with men 0.67 0.48, 0.94 -- -- 
     Heterosexual (ref) 1.00 -- -- -- 
     Injection drug users 1.11 0.83, 1.50 -- -- 
     Other/Unknown 0.89 0.58, 1.38 -- -- 
Hepatitis C infection 1.24 0.95, 1.63 0.98 0.69, 1.38 
Hepatitis B infection 0.99 0.64, 1.52 0.97 0.57, 1.63 
Cigarette smoking 1.47 1.01, 2.13 1.23 0.81, 1.87 
Diabetes 0.90 0.65, 1.25 0.93 0.60, 1.44 
Hypertension 0.67 0.52, 0.87 0.70 0.50, 0.99 
Elevated total cholesterol 1.20 0.94, 1.55 1.55 1.13, 2.13 
Statin prescription 0.61 0.41, 0.91 0.69 0.40, 1.20 
History of clinical AIDS  2.59 2.00, 3.35 2.35 1.66, 3.34 
CD4 count (cells/µl)          <200 (ref) 1.00 -- 1.00 -- 
     200-349 0.64 0.46, 0.88 0.83 0.55, 1.24 
     350-499 0.56 0.37, 0.83 0.81 0.51, 1.29 
     ≥500 0.34 0.21, 0.55 0.47 0.26, 0.86 
Detectable HIV RNA 3.32 2.35, 4.70 1.79 1.17, 2.73 
ART Use 0.15 0.11, 0.22 0.13 0.08, 0.20 
Prior tenofovir prescription 1.27 0.89, 1.80 1.69 1.08, 2.63 
Bold signifies statistical significance (p-value <0.05) 
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Figure 3. Kaplan-Meier Survival Estimate of HIV+ ESRD patients in NA-ACCORD  
 
 
Figure 4. Kaplan-Meier Survival Estimate of HIV+ ESRD patients in NA-
ACCORD, by Race 
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Figure 5. Kaplan-Meier Survival Estimate of HIV+ ESRD patients in NA-
ACCORD, by Sex 
 
 
Log-rank p-value: 0.33 
 
Figure 6. Kaplan-Meier Survival Estimate of HIV+ ESRD patients in NA-
ACCORD, by Baseline Age 
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20-29 0.0315 24.8333 0.7823 2 
30-39 0.0443 224.5000 9.9491 29 
40-49 0.0685 453.9167 31.1009 36 
50-59 0.1080 355.7500 38.4329 31 
60-64 0.1501 62.6667 9.4063 8 
65-69 0.1946 42.5833 8.2860 4 
70-74 0.2512 21.0000 5.2745 1 
75-79 0.3239 2.8333 0.9176 2 
80-84 0.4106 0.0000 0.0000 0 
85+ 0.5262 0.3333 0.1754 1 
Total   104.3248 114 
  Age-specific SMR: 1.0927 95% CI: (0.89, 1.29) 
MR = mortality rate 
Mortality rates are from 2014 USRDS data, retrieved from http://www.usrds.org/reference.aspx, Table H.2 
NA-ACCORD person-years are derived from person-months divided by 12 
 
 
















Male 0.1592 854.0833 135.9274 78 
Female 0.1680 338.2500 56.8204 36 
Total   192.7477 114 
  Sex-specific SMR: 0.5914 95% CI: (0.48, 0.70) 
MR = mortality rate 
Mortality rates are from 2014 USRDS data, retrieved from http://www.usrds.org/reference.aspx, Table H.2 
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White 0.1791 84.9167 15.2043 9 
Black 0.1445 961.5000 138.9207 99 
Other 0.1215 145.9167 17.7289 6 
Total   171.8539 114 
  Race-specific SMR: 0.6634 95% CI: (0.52, 0.79) 
MR = mortality rate 
Mortality rates are from 2014 USRDS data, retrieved from http://www.usrds.org/reference.aspx, Table H.2 

































	   50	  
Margaret C. Cantara 
501 St. Paul Street, Apartment 306 





PROFILE      
Master of Health Science candidate concentrating in infectious disease epidemiology, 
with a research focus on HIV/AIDS. Certified HIV tester and counselor in the state of 
Maryland. Particular interest in social and behavioral aspects of health behaviors, 
including prevention, care-seeking, and treatment, particularly in marginalized 
populations. Strong quantitative and qualitative epidemiological skills. 
 
 
EDUCATION        
Master of Health Science in Epidemiology (MHS), GPA: 3.89/4.0      
Expected May 2015 
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 
Concentration: Infectious Disease Epidemiology 
Relevant Coursework (to be completed by May 2015): 4 terms of Epidemiologic 
Methods; 4 terms of Biostatistics; 4 Terms of Infectious Disease Epidemiology; 2 Terms 
of HIV/AIDS Epidemiology; 1 Term of Genetic Epidemiology; Practical Skills in 
Conducting Research in Clinical Epidemiology; Epidemiologic Inference in Outbreak 
Investigations; Psychosocial Factors in Health and Illness; Introduction to the U.S. 
Healthcare System; Professional Epidemiology 
Honors: Delta Omega, Master’s Tuition Scholarship 
 
Bachelor of Arts in Comparative Human Development, GPA: 3.89/4.0   
        June 2013 
The University of Chicago, Chicago, IL 
Honors: Phi Beta Kappa (Junior Year); Dean’s List 2010, 2011, 2012, 2013 
 
 
WORK EXPERIENCE          
Research Assistant                     
August 2014 – Present 
Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, 
Baltimore, MD 
• Analyze patient data from The North American AIDS Cohort Collaboration on 
Research and Design (NA-ACCORD) to characterize survival after End Stage Renal 
Disease (ESRD) diagnosis in HIV positive individuals 
• Compare age-, sex-, and race-adjusted mortality rates after ESRD diagnosis in HIV 
positive adults with that of the general population utilizing SAS and Stata software 
packages 
 
	   51	  
Teaching Assistant, Principles of Epidemiology            
July 2014 – August 2014 
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 
• Led laboratory sessions two times per week, introducing new concepts and answering 
lab-specific questions                 
• Tutored students on concepts introduced in lectures during established office hours 
once per month 




HIV Tester and Counselor             
October 2013 – May 2014 
Johns Hopkins Children’s Center Harriet Lane Clinic, Baltimore, MD                   
• Administered OraQuick (oral) or Clearview (blood) rapid HIV test; provided patients 
with HIV test results and appropriate information concerning next steps 
• Educated and counseled patients about HIV/STD risk reduction behaviors and 
strategies; provided reproductive health options to patients; connect patients to 
relevant resources or sources of information 
 
Research Assistant              
October 2012 – June 2013 
The University of Chicago Medical Center, Section of Infectious Diseases, Chicago, IL 
• Collected and analyzed data for Dr. Michael David for the purpose of identifying risk 
factors for recurrent community-associated MRSA infections 
• Compiled quantitative and qualitative data from the University of Chicago Medical 
Center doctors and past patients for an NIH-funded prospective cohort study on 
recurrent infections 
 
Research Assistant              
June 2011 – October 2011 
The Harris School of Public Policy Studies at the University of Chicago, Chicago, IL 
• Collected and interpreted sociological data analyzing the impact of economic 
disparities on education throughout the world through a collaboration with Professors 
Susan Mayer and Leonard Lopoo (Syracuse University) 
• Compared social and economic variables among the 50 states and among OECD 
countries using Microsoft Excel 
 
Teaching Assistant, Eliminating Infectious Disease                  September 
2010 – December 2010 
University of Chicago, The Division of Biological Sciences, Chicago, IL                          
• Tutored students during personal office hours four times per week for between two to 
three hours per day; coordinated review sessions; held office hours; corrected 
students’ term papers and examinations 
 
 
	   52	  
LEADERSHIP ACTIVITIES         
Project Manager                   
October 2013 – Present 
Thread, Baltimore, MD        
• Lead group of volunteers as head mentor for an underperforming Baltimore high 
school student 
• Oversee and collaborate with team of mentors to help student achieve academic and 
social goals  
• Work with Program Coordinator to develop and execute project plans and timelines 
• Connect with external contacts as needed to provide personal support for student 
mentee 
 
Social Chair                
September 2014 – Present 
Epidemiology Student Organization, Johns Hopkins Bloomberg School of Public Health, 
Baltimore, MD 
• Establish quarterly inter- and intra-department events including annual department-
wide picnic 




PROFESSIONAL DEVELOPMENT        
Computer Skills: Stata; SAS; PC and Mac Microsoft Word, Excel, and PowerPoint 
Certifications: Maryland Department of Health and Mental Hygiene, Prevention and 
Health Promotion Administration’s HIV 101 Training for Testing and Counseling 
Language: Proficient in French 
 
	  
